MIM
PRCT icon

MetLife Investment Management’s Procept Biorobotics PRCT Stock Holding History

MetLife Investment Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$778K Buy
34,471
+4,595
+15% +$115K ﹤0.01% 1652
2026
Q1 		$747K Sell
29,876
-224
-0.7% -$6.31K ﹤0.01% 1553
2025
Q4 		$947K Sell
30,100
-1,344
-4% -$44.6K ﹤0.01% 1460
2025
Q3 		$1.12M Hold
31,444
– – 0.01% 1372
2025
Q2 		$1.81M Buy
31,444
+5,114
+19% +$289K 0.01% 1038
2025
Q1 		$1.53M Sell
26,330
-350
-1% -$23.9K 0.01% 1165
2024
Q4 		$2.15M Buy
26,680
+2,144
+9% +$183K 0.01% 998
2024
Q3 		$1.97M Hold
24,536
– – 0.01% 1025
2024
Q2 		$1.5M Buy
24,536
+4,060
+20% +$241K 0.01% 1124
2024
Q1 		$1.01M Sell
20,476
-860
-4% -$40.9K 0.01% 1294
2023
Q4 		$894K Buy
21,336
+2,142
+11% +$72.9K 0.01% 1358
2023
Q3 		$630K Hold
19,194
– – ﹤0.01% 1483
2023
Q2 		$679K Buy
19,194
+5,396
+39% +$178K ﹤0.01% 1494
2023
Q1 		$392K Hold
13,798
– – ﹤0.01% 1797
2022
Q4 		$573K Hold
13,798
– – ﹤0.01% 1557
2022
Q3 		$572K Hold
13,798
– – ﹤0.01% 1544
2022
Q2 		$451K Buy
13,798
+8,790
+176% +$320K ﹤0.01% 1732
2022
Q1 		$175K Buy
+5,008
New +$121K ﹤0.01% 2435

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

MetLife Investment Management's PRCT Position: Q2 2026 in Review

MetLife Investment Management increased its Procept Biorobotics (PRCT) stake by 15% in Q2 2026, buying an estimated $115K and bringing the position to 34,471 shares worth $778K. The position accounts for ﹤0.01% of the portfolio, ranked #1652.

MetLife Investment Management first reported a position in PRCT in Q1 2022 and has held it in 18 quarters since. The position peaked at $2.15M in Q4 2024. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • MetLife Investment Management held 34,471 shares of Procept Biorobotics worth $778K as of Q2 2026.
  • MetLife Investment Management bought 4,595 Procept Biorobotics shares in Q2 2026, an estimated $115K.
  • Procept Biorobotics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1652 holding.
  • MetLife Investment Management first reported a position in Procept Biorobotics in Q1 2022 and has held it in 18 quarters since.
  • MetLife Investment Management's Procept Biorobotics position peaked at $2.15M in Q4 2024.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.